Mode
Text Size
Log in / Sign up
Phase 4 N=70 Randomized Treatment

Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women

UTI

Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Eligible Subjects That Were Enrolled in the Study — 70 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Antibiotics (Drug)
Age
Older Adult · 65+ yrs
Sex
Female
Sponsor
Megan Bradley
Primary completion
Aug 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Eligible Subjects That Were Enrolled in the Study
70
SECONDARY
Number of Persons That Were Screened for Participation
131
SECONDARY
Proportion of Persons Screened Who Met Inclusion/Exclusion Criteria
103
SECONDARY
Proportion of Persons Screened Who Declined Participation or Were Ineligible
43
SECONDARY
Proportion of Participants Enrolled Who Completed the Study
30; 31 .78
SECONDARY
Monthly Enrollment Rate
4
SECONDARY
Proportion of Enrolled Participants That Completed All Study Procedures
30; 31 .78
SECONDARY
Proportion of Enrolled Participants That Took Alternative Agents for Management of Symptoms
16; 10 .68
SECONDARY
Proportion of Participants in the Culture-directed Arm That Acquired Off-protocol Antibiotics for Their Symptoms
1
SECONDARY
Proportion of Enrolled Participants That Completed Electronic Surveys
30; 31 .78

Summary

To evaluate the feasibility of recruiting eligible subjects into a randomized trial of a culture-directed versus empiric antibiotic strategy for patient-reported urinary tract infection symptoms in older women and the adherence to study procedures.

Eligibility Criteria

Inclusion Criteria

  • Female biologic Sex
  • Age ≥65 years old
  • History of recurrent UTI per patient report of greater than 2 UTIs in the last 6 months or 3 UTIs in the last year
  • Patient reported UTI defined as:
  • Dysuria, increased urinary urgency/frequency and/or suprapubic pain

Exclusion Criteria

  • Male biologic sex
  • Age 20mg/day of prednisone)
  • Previous solid organ transplant
  • Provider concern for pyelonephritis and/or sepsis (i.e., fevers)
  • Unwilling or unable to comply with study procedures
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05726318). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search